Effects of olanzapine, fluoxetine and olanzapine/fluoxetine on creatine kinase activity in rat brain

Brain Research Bulletin

Volumn 80, Issue 6, 2009, Pages 337-340

  Agostinho, Fabiano R ^a   Scaini, Giselli ^a   Ferreira, Gabriela K ^a   Jeremias, Isabela C ^a   Réus, Gislaine Z ^a   Rezin, Gislaine T ^a   Castro, Adalberto A ^a   Zugno, Alexandra I ^a   Quevedo, João ^a   Streck, Emilio L ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

Creatine kinase; Fluoxetine; Olanzapine

Indexed keywords

CREATINE KINASE; FLUOXETINE; OLANZAPINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HIPPOCAMPUS; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN; CREATINE KINASE, BB FORM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FLUOXETINE; MALE; RATS; RATS, WISTAR; SEROTONIN UPTAKE INHIBITORS;

EID: 70349952161     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2009.09.002     Document Type: Article

References (40)

1. Aksenov M., Aksenov M., Butterfield D.A., and Markesbery W.R. Oxidative modification of creatine kinase BB in Alzheimer's disease brain. J. Neurochem. 74 (2000) 2520-2527
2. Albert K.A., Hemmings H.C., Adamo A.I., Potkin S.G., Akbarian S., Sandman C.A., Cotman C.W., Bunney Jr. W.E., and Greengard P. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Arch. Gen. Psychiatry 59 (2002) 705-712
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (1994), American Psychiatric Press, Washington, DC
4. Assis L.C., Scaini G., Di-Pietro P.B., Castro A.A., Comim C.M., Streck E.L., and Quevedo J. Effect of antipsychotics on creatine kinase activity in rat brain. Basic Clin. Pharmacol. Toxicol. 101 (2007) 315-319
5. Belmaker H. Bipolar disorder. N. Engl. J. Med. 351 (2004) 476-486
6. Bessman S.P., and Carpenter C.L. The creatine-creatine phosphate energy shuttle. Annu. Rev. Biochem. 54 (1985) 831-865
7. David S., Shoemaker M., and Haley B.E. Abnormal properties of creatine kinase in Alzheimer's disease brain: correlation of reduced enzyme activity and active site photolabeling with aberrant cytosol-membrane partitioning. Mol. Brain Res. 54 (1998) 276-287
8. Fatemi S.H., Laurence J.A., Araghi-Niknam M., Stary J.M., Schulz S.C., Lee S., and Gottesman I.I. Glial fibrillary acidic protein is reduced in cerebellum of subjects with major depression, but not schizophrenia. Schizophr. Res. 69 (2004) 317-323
9. Fava M. New approaches to the treatment of refractory depression. J. Clin. Psychiatry 61 (2000) 26-32
10. Gross W.L., Bak M.I., Ingwall J.S., Arstall M.A., Smith T.W., Balligand J.L., and Kelly R.A. Nitric oxide inhibits creatine kinase and regulates rat heart contractile reserve. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 5604-5609
11. Hamman B.L., Bittl J.A., Jacobus W.E., Allen P.D., Spencer R.S., Tian R., and Ingwall J.S. Inhibition of the creatine kinase reaction decreases the contractile reserve of isolated rat hearts. Am. J. Physiol. 269 (1995) 1030-1036
12. Hirschfeld R.M., Montgomery S.A., and Aguglia E. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J. Clin. Psychiatry 63 (2002) 826-837
13. Hughes B.P. A method for estimation of serum creatine kinase and its use in comparing creatine kinase and aldolase activity in normal and pathologic sera. Clin. Chim. Acta 7 (1962) 597-604
14. Kato T., and Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord. 2 (2000) 180-190
15. Keck P.E., and McElroy S.L. Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J. Clin. Psychiatry 64 (2003) 1426-1435
16. Konradi C., Eaton M., MacDonald M.L., Walsh J., Benes F.M., and Heckers S. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch. Gen. Psychiatry 61 (2004) 300-308
17. Kupfer D.J. Dimensional models for research and diagnosis: a current dilemma. J. Abnorm. Psychol. 114 (2005) 557-559
18. Lowry O.H., Rosebough N.G., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
19. Machado-Vieira R., Lara R.D., Portela L.V., Gonçalves C.A., Soares J.C., Kapczinski F., and Souza D.O. Elevated serum S100B protein in drug-free bipolar patients during first manic episode: a pilot study. Eur. Neuropsychopharmacol. 12 (2002) 269-272
20. Martins M.R., Petronilho F.C., Gomes K.M., Dal-Pizzol F., Streck E.L., and Quevedo J. Antipsychotic-induced oxidative stress in rat brain. Neurotox. Res. 13 (2008) 63-69
21. Matthews J.D., Bottonari K.A., and Polania L.M. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. J. Clin. Psychiatry 63 (2002) 1164-1170
22. Morishita S. Clonazepam as a therapeutic adjunct to improve the management of depression: a brief review. Hum. Psychopharmacol. 24 (2009) 191-198
23. Müller-Oerlinghausen B., and Roggenbach J. Bipolar disorder. Lancet 359 (2002) 241-247
24. Nelson G., Hall G.B., and Forchuk C. Current and preferred housing of psychiatric consumers/survivors. Can. J. Commun. Ment. Health 22 (2003) 5-19
25. Prabakaran S., Swatton J.E., Ryan M.M., Huffaker S.J., Huang J.T., Griffin J.L., Wayland M., Freeman T., Dudbridge F., Lilley K.S., Karp N.A., Hester S., Tkachev D., Mimmack M.L., Yolken R.H., Webster M.J., Torrey E.F., and Bahn S. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry 9 (2004) 684-697
26. Rezin G.T., Amboni G., Zugno A.I., Quevedo J., and Streck E.L. Mitochondrial dysfunction and psychiatric disorders. Neurochem. Res. 34 (2009) 1021-1029
27. Rezin G.T., Cardoso M.R., Gonçalves C.L., Scaini G., Fraga D.B., Riegel R.E., Comim C.M., Quevedo J., and Streck E.L. Inhibition of mitochondrial respiratory chain in brain of rats subjected to an experimental model of depression. Neurochem. Int. 53 (2008) 395-400
28. Rothermundt M., Missler U., Arolt V., Peters M., Leadbeater J., Wiesmann M., Rudolf S., Wandinger K.P., and Kirchner H. Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol. Psychiatry 6 (2001) 445-449
29. Schatzberg A.F. New approaches to managing psychotic depression. J. Clin. Psychiatry 64 (2003) 19-23
30. Schnyder T., Gross H., Winkler H., Eppenberger H.M., and Wallimann T. Crystallization of mitochondrial creatine kinase. Growing of large protein crystals and electron microscopic investigation of microcrystals consisting of octamers. J. Biol. Chem. 266 (1991) 5318-5322
31. Seager M.A., Barth V.N., Phebus L.A., and Rasmussen K. Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder. Psychopharmacology (Berl.) 181 (2005) 126-133
32. Shelton R.C. The combination of olanzapine and fluoxetine in mood disorders. Expert Opin. Pharmacother. 4 (2003) 1175-1183
33. Shelton R.C. The return of fixed combinations in psychiatry: fluoxetine and olanzapine combination. Ther. Clin. Risk. Manag. 2 (2006) 187-192
34. Shelton R.C., Tollefson G.D., Tohen M., Stahl S., Gannon K.S., Acobs T.G., Buras W.R., Bymaster F.P., Zhang W., Spencer K.A., Feldman P.D., and Meltzer H.Y. A novel augmentation strategy for treating resistant major depression. Am. J. Psychiatry 158 (2001) 131-134
35. Shelton R.C., and Tomarken A.J. Can recovery from depression be achieved?. Psychiatr. Serv. 52 (2001) 1469-1478
36. Streck E.L., Amboni G., Scaini G., Di-Pietro P.B., Rezin G.T., Valvassori S.S., Luz G., Kapczinski F., and Quevedo J. Brain creatine kinase activity in an animal model of mania. Prog. Neuropsychopharmacol. Biol. Psychiatry 31 (2007) 887-891
37. Szasz B.K., Mike A., Karoly R., Gerevich Z., Illes P., Vizi E.S., and Kiss J.P. Direct inhibitory effect of fluoxetine on N-methyl-d-aspartate receptors in the central nervous system. Biol. Psychiatry 62 (2007) 1303-1309
38. Tohen M., Vieta E., and Calabrese J. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry 60 (2003) 1079-1088 (erratum in: Arch. Gen. Psychiatry 61 (2004) 176)
39. Tomimoto H., Yamamoto K., Homburger H.A., and Yanagihara T. Immunoelectron microscopic investigation of creatine kinase BB-isoenzyme after cerebral ischemia in gerbils. Acta Neuropathol. 86 (1993) 447-455
40. Wallimann T., Wyss M., Brdiczka D., Nicolay K., and Eppenberger H.M. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. Biochem. J. 281 (1992) 21-40